Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

Overview
Date Founded

1990

Headquarters

Strides House,Bannerghatta Road,Bilekahalli,Bangalore, Karnataka 560076

Type of Company

Public

Employees (Worldwide)

4,429

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company was founded by Arun N. Kumar on June 28, 1990 and is headquartered in Bangalore, India.

Contact Data
Trying to get in touch with decision makers at Strides Pharma Science Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Managing Director & Chief Executive Officer

Chief Financial Officer, Executive Director

Chief Executive Officer, Africa Operations

President-Brands India

Chief Executive Officer-Pharma

Company Secretary & Compliance Officer

Chief Executive Officer, Agila Specialties

Chief Executive Officer-CNS Business

Chief Financial Officer, API & Crams

Board of Directors

Founder at Strides Pharma Science Ltd.

Group Chief Executive Officer at TRAFCO Group BSC

Former Executive Director, Director, Finance & Chief Financial Officer at Exide Industries Ltd.

Former Country Head at Symphony Asia Holdings Pte Ltd.

President at Bombay Natural History Society

Adjunct Professor at The Indian Institute of Technology - Jodhpur

Paths to Strides Pharma Science Ltd.
Potential Connections via
Relationship Science
You
Strides Pharma Science Ltd.
Owners & Shareholders
Details Hidden

ABSLAMC is a long-term, fundamental research-based investor which manages portfolios invested in equity, fixed-income and money-market instruments across regions and sectors. These assets are available via a wide range of financial vehicles including diversified or sector specific equity funds, fund of funds, hybrid and monthly income funds, debt and treasury products and offshore funds. These funds can be actively or passively managed. The firm’s equity fund invests in stocks/equity shares of companies of different market capitalization. Their debt mutual fund invests in a mix of debt investments such as treasury bills, government securities (G-Secs), corporate bonds and other money market instruments of varying maturities that seek to provide investors capital preservation and regular income. ABSLAMC’s hybrid fund invests in a mix of growth oriented equity, capital preserving debt and other assets related instruments, which can vary proportionally over time or remain fixed.

Details Hidden

Route One Investment Co. employs a global value-oriented investment management strategy. The firm invests in and trades securities and commodities consisting mainly of equity, equity-related and credit securities that are traded publicly and privately in U.S. and non-U.S. markets. Route One expects to invest a portion of the funds' assets in illiquid securities, which generally are restricted securities of public and private companies. They also invest in preferred stocks, convertible securities, warrants, rights, options (including covered and uncovered puts and calls and over-the-counter options), swaps and other derivative instruments, bonds and other fixed income securities, non-U.S. currencies, futures, options on futures, other commodity interests and money market instruments. Route One also engages in short-selling, margin trading, hedging and other investment strategies.

Details Hidden

Weiss Asset Management seeks to achieve high risk-adjusted returns while attempting to reduce risk. The firm's primary investment strategy is designed to purchase securities at a discount to observable and measurable reference values. The private funds tend to focus on economic arbitrage trades, but they may trade trade in a wider range of financial instruments, assets and securities and types of trades and may employ such trading techniques as option transactions, margin transactions, short sales, forwards, leverage, and other derivatives trading. The private funds invest primarily in non-U.S. markets, including emerging markets throughout the world.Weiss Asset Management's AIM-Listed Fund's investment objective is to provide shareholders with an attractive return on their investment predominantly through long-term capital appreciation, but the fund also seeks to return to shareholders dividends received on an annual basis. The fund is geographically focused on South Korean companies and specifically invests mainly in listed preferred shares issued by companies incorporated in South Korea, which in many cases are currently trading at a discount to the corresponding common shares of the same companies. Weiss generally seeks to build a portfolio of South Korean preferred shares that they believe are undervalued and could appreciate based on criteria they select.

Recent Transactions
Details Hidden

purchases Strides Pharma Science Ltd. /Biotech Bus from Strides Pharma Science Ltd.

Details Hidden

Strides Pharma Science Ltd., Agnus Capital LLP purchase Sequent Scientific Ltd.

Details Hidden

Apotex Pharmaceutical Holdings, Inc., Apotex Pty Ltd. purchase Arrow Pharmaceuticals Pty Ltd. from Strides Pharma Science Ltd.

Transaction Advisors
Legal Advisor

Advised onStrides Pharma Science Ltd. purchases Shasun Pharmaceuticals Ltd.

Investment Advisor

Advised onStrides Pharma Science Ltd., Solara Active Pharma Sciences Ltd. purchase SeQuent Scientific Ltd /Humana API Business from Sequent Scientific Ltd.

Legal Advisor

Advised onApotex Pharmaceutical Holdings, Inc., Apotex Pty Ltd. purchase Arrow Pharmaceuticals Pty Ltd. from Strides Pharma Science Ltd.

Legal Advisor

Advised onMylan, Inc. purchases Agila Specialties Pvt Ltd. from Strides Pharma Science Ltd.

Investment Advisor

Advised onMylan, Inc. purchases Agila Specialties Pvt Ltd. from Strides Pharma Science Ltd.

Legal Advisor

Advised onMylan, Inc. purchases Agila Specialties Pvt Ltd. from Strides Pharma Science Ltd.

Advisors & Consultants
Advisor

Senior Adviser, Asia at The Carlyle Group, Inc.

Legal Advisor

Partner at Herbert Smith Freehills LLP

Legal Advisor

Partner at Herbert Smith Freehills LLP

Clients

Population Services International is a nonprofit company headquartered in Washington, DC, that operates as global health organization with programs targeting malaria, child survival, HIV, and reproductive health. It was founded by Philip D. Harvey. Karl Hofmann is currently the CEO of the firm.The company says this about itself: PSI is a leading global health organization working in malaria, HIV, modern contraception and reproductive health, non-communicable diseases and sanitation.

Partnership for Supply Chain Management, Inc. provides health care services. The company was founded in 1982 and is headquartered in Arlington, VA .

The Global Fund is an innovative financing institution that provides funding to countries to support programs that prevent, treat and care for people with HIV and AIDS, tuberculosis and malaria. Whether it is distributing mosquito nets to protect families from malaria in Honduras, training peer counsellors who work with teenagers diagnosed with HIV in South Africa, or providing equipment for the diagnosis of tuberculosis to clinics in Kazakhstan, partners in each country fighting the pandemics find support from the Global Fund. The Global Fund to Fight AIDS, Tuberculosis and Malaria was created in 2002 to dramatically increase resources for the fight against the three pandemics. It spurs partnerships between government, civil society, the private sector and communities living with the diseases, the most effective way to fight these deadly infectious diseases. The Global Fund does not manage or implement programs on the ground, relying instead on local experts. It works with partners to ensure that funding serves the men, women and children affected by these diseases in the most effective way.

Key Stats and Financials As of 2020
Market Capitalization
$998M
Total Enterprise Value
$639M
Earnings Per Share
$0.04
EBITDAMargin
13.34%
Enterprise Value / Sales
1.8x
Enterprise Value EBITDAOperating
13.51x
TEVNet Income
200.25x
Debt TEV
0.46x
Three Year Compounded Annual Growth Rate Of Revenue
-8.34%
Revenue
$355M
Total Equity
$343M
Total Debt
$295M
Net Profit
$3.19M
EBITDA
$47.3M
Investments
Details Hidden

Inbiopro Solutions Pvt Ltd. provides research and development services in the biology and engineering sector. The company was founded by Aditya Julka in 2007 and is headquartered in Bangalore, India.

Suppliers
Ess Dee Aluminium Ltd. Paper Products | Mumbai, India

Ess Dee Aluminium Ltd. is a holding company, which engages in the manufacture of packaging materials for pharmaceutical, food, and fast-moving consumer goods industries. It specializes in cold form blister and child-resistant-blister packaging. The company was founded in 1991 and is headquartered in Mumbai, India.

Suda Pharmaceuticals Ltd. Pharmaceuticals | Osborne Park, Australia

Suda Pharmaceuticals Ltd. develops pharmaceuticals and distributes medical devices and consumables. Its activities include pharmaceutical development of drug delivery technology and medical devices and consumables distribution. The company operates through following business segment: Suda; and Malaria Research Company. The Suda segment includes research and development to create new human pharmaceutical products by combining proven drugs with innovated, patented, delivery technologies. The Malaria Research Company segment segment is the pharmaceutical development segment for the treatment of malaria. Suda Pharmaceuticals was founded on December 21, 1999 and is headquartered in Osborne Park, Australia.

Solara Active Pharma Sciences Ltd. Pharmaceuticals | Chennai, India

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. Its products include NSAID, anaesthetic, analgesics, antiviral, retinod, anti-emetic, antimalrial, diuretic, muscle relaxant, antiallergics, antihypertensive, calcimimetic agent, anti sezure, antigout, cardiovascular, anti-infective, cough suppressant, anti-ulcerative, anesthetic, antiepileptic, antirheumatic, skin disorder, cardiovascular agent, aplha or beta antagonist, hyperphosphatamia, atypical antipsychotic, antineoplastic adjunct, anti psoriasis, barbiturate dervicative, treatment of overactive bladder, gastro-intestinal, atypical antipsychotic, antihyperlipidemic, antihelmintic, gastrointestinal, antibiotic, phenylalanine reducer, anticholetithic, and anti depressant. The company was founded on February 23, 2017 and is headquartered in Chennai, India.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Strides Pharma Science Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Strides Pharma Science Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Strides Pharma Science Ltd..